Stock GLUE MONTE ROSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Delayed Nasdaq
Other stock markets
 12:01:23 2024-05-23 pm EDT 		5-day change 1st Jan Change
4.17 USD -0.95% Intraday chart for Monte Rosa Therapeutics, Inc. -20.11% -26.19%
May. 16 Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
May. 16 Monte Rosa Therapeutics Prices $100 Million Public Offering MT

Evolution of the average Target Price on Monte Rosa Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fd45adcf96b531.7R6eXYl2-ZSQ6uYYsVVCJybxwpTKZrWu6q6FWqG8P8w.nVPyLegdzNfU2d98gAEScHPIgMb5MeGb2uPsFPLRefSIK9IeuD-I96GEtw~308914a47fc4d081fa542b3cdafbc3eb

Analyst Recommendations on Monte Rosa Therapeutics, Inc.

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating MT
Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target MT
Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating MT
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18 MT
UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target MT
Jefferies Starts Monte Rosa Therapeutics at Buy With $20 Price Target MT
Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating MT
Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target MT
Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating MT
Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target MT
Guggenheim Adjusts Price Target for Monte Rosa Therapeutics to $35 From $40, Maintains Buy Rating MT
Berenberg Bank Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $32 Price Target MT
MONTE ROSA THERAPEUTICS : SVB Leerink Starts Monte Rosa Therapeutics at Market Perform with $20 Price Target MT
MONTE ROSA THERAPEUTICS : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target MT
MONTE ROSA THERAPEUTICS : Cowen Initiates Coverage on Monte Rosa Therapeutics With Outperform Rating MT
MONTE ROSA THERAPEUTICS : Piper Sandler Starts Monte Rosa Therapeutics at Overweight With $40 Price Target MT
MONTE ROSA THERAPEUTICS : Guggenheim Starts Monte Rosa Therapeutics at Buy With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.21 USD
Average target price
15 USD
Spread / Average Target
+256.29%
High Price Target
20 USD
Spread / Highest target
+375.06%
Low Price Target
9 USD
Spread / Lowest Target
+113.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Monte Rosa Therapeutics, Inc.

UBS
Wedbush
Credit Suisse
Wells Fargo Securities
Jefferies & Co.
Piper Sandler
Berenberg Bank
Guggenheim
SVB Leerink
Cowen
JPMorgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GLUE Stock
  4. Consensus Monte Rosa Therapeutics, Inc.